Stockholders' Equity - Additional Information (Detail) - USD ($)
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
Apr. 07, 2017 |
Sep. 09, 2016 |
Mar. 31, 2017 |
Jan. 31, 2017 |
Jan. 31, 2016 |
Jun. 30, 2017 |
Jun. 30, 2016 |
Jun. 30, 2017 |
Jun. 30, 2016 |
Dec. 31, 2016 |
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period |
|
|
|
|
|
85.00%
|
|
85.00%
|
|
|
| Employee Stock Purchase Plan to eligible employees, compensation expense recognized |
|
|
|
|
|
$ 40,000
|
$ 30,000
|
$ 75,000
|
$ 56,000
|
|
| General and Administrative Expense |
|
|
|
|
|
$ 8,524,000
|
6,637,000
|
16,509,000
|
12,666,000
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
$ 3,200,000
|
2,400,000
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
$ 4.02
|
|
$ 4.02
|
|
|
| Share-based Compensation |
|
|
|
|
|
|
|
$ 7,736,000
|
5,889,000
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate |
|
|
|
|
|
|
|
0.00%
|
|
|
| Warrants Issued |
|
|
|
853,677
|
|
|
|
|
|
|
| Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Percentage Of Placement Agent Fee |
|
|
10.00%
|
|
|
|
|
|
|
|
| Payments of Stock Issuance Costs |
|
|
$ 42,000
|
|
|
|
|
|
|
|
| Longterm Incentive Program [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value |
|
|
|
|
|
|
|
$ 1,500,000
|
|
$ 1,400,000
|
| Capital Units, Authorized |
|
|
|
100,000,000
|
|
|
|
|
|
|
| Consultants [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
$ 4,300,000
|
3,500,000
|
|
| Checkpoint [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
$ 2,400,000
|
|
|
|
|
| Dr. Rosenwald [Member] | Longterm Incentive Program [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period |
|
|
|
552,698
|
510,434
|
|
|
|
|
|
| Mustang [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Proceeds from Issuance of Private Placement |
|
|
|
$ 8,536,774
|
|
|
|
|
|
|
| Mustang [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
$ 8.50
|
|
$ 8.50
|
|
|
| Stock Issued During Period, Value of Warrants Excercised |
|
|
|
|
|
|
|
$ 65,000
|
|
|
| Avenue Therapeutics, Inc. [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Research And Development Expense |
|
|
|
|
|
$ 10,000
|
4,000
|
12,000
|
9,000
|
|
| General and Administrative Expense |
|
|
|
|
|
10,000
|
4,000
|
12,000,000,000
|
9,000
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
19,000
|
9,000
|
24,000
|
18,000
|
|
| Proceeds from issuance of Common stock |
|
|
|
|
|
|
|
34,500,000
|
|
|
| Mustang Bio, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross |
200,000
|
|
|
|
|
|
|
|
|
|
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options |
|
|
|
|
|
2,100,000
|
|
$ 2,100,000
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate |
0.00%
|
|
|
|
|
|
|
|
|
|
| Aggregate Number of Shares of Common Stock,Percentage |
|
|
|
|
|
|
|
2.50%
|
|
|
| Stock Issuance Costs |
|
|
|
|
|
|
|
$ 1,200,000
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Description |
|
|
|
|
|
|
|
Both grants have the following vesting schedule: 50% of the options vest over-time with 25% vesting over 12 months of continued service, with the remaining 25% vesting in 12 equal installments thereafter, subject to continued employment. The remaining 50% vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the grant vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Mustang product candidate, (ii) 25% of the grant vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Mustang product candidate, (iii) 25% of the grant vest upon Mustangs achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the grant vest upon Mustangs achievement of a fully-diluted market capitalization of $1,000,000,000.
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
|
9 years 9 months 22 days
|
|
|
| Mustang Bio, Inc [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period Shares warrants Exercised |
|
|
|
|
|
|
|
2,500
|
|
|
| Mustang Bio, Inc [Member] | Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross |
1,041,675
|
|
|
|
|
|
|
|
|
|
| Mustang Bio, Inc [Member] | Employee [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price |
$ 5.73
|
|
|
|
|
|
|
|
|
|
| Mustang Bio, Inc [Member] | Non-employee [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition |
|
|
|
|
|
|
|
1 year 9 months 18 days
|
|
0 years
|
| Share-based Compensation |
|
|
|
|
|
|
|
$ 2,800,000
|
2,800,000
|
$ 0
|
| Journey Medical Corporation [Member] | Employee [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures |
|
|
|
|
|
|
|
320,000
|
|
|
| Journey Medical Corporation [Member] | Non-employee [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition |
|
|
|
|
|
|
|
1 year 2 months 12 days
|
|
10 months 24 days
|
| Share-based Compensation |
|
|
|
|
|
|
|
$ 200,000
|
200,000
|
|
| Checkpoint Therapeutics, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
800,000
|
3,400,000
|
1,900,000
|
|
| Share-based Compensation |
|
|
|
|
|
1,900,000
|
500,000
|
2,400,000
|
1,200,000
|
|
| JMC [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
73,000
|
147,000
|
119,000
|
328,000
|
|
| Helocyte Inc [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
34,000
|
93,000
|
$ 81,000
|
93,000
|
|
| Helocyte Inc [Member] | Non-employee [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition |
|
|
|
|
|
|
|
0 years
|
|
11 days
|
| Share-based Compensation |
|
|
|
|
|
25,000
|
68,000
|
$ 62,000
|
68,000
|
$ 33,000
|
| Cellvation Inc [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
6,000
|
|
14,000
|
|
|
| Cellvation Inc [Member] | Non-employee [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation |
|
|
|
|
|
2,000
|
|
5,000
|
|
|
| National Holdings Corporation [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
$ 183,000
|
|
$ 183,000
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
$ 3.25
|
|
$ 3.25
|
|
|
| National Holdings Corporation [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Percentage Of Placement Agent Fee |
|
10.00%
|
|
|
|
|
|
|
|
|
| Proceeds from Issuance of Private Placement |
|
|
|
$ 55,500,000
|
|
|
|
|
|
|
| Warrants Issued |
|
|
|
2,134,193
|
|
|
|
|
|
|
| Private Placement Stock Units Shares To Be Issued |
|
|
|
|
|
10,000
|
|
10,000
|
|
|
| Percentage Of Shares Issued To Placement Agent |
|
|
|
10.00%
|
|
|
|
|
|
|
| National Holdings Corporation [Member] | Mustang Bio, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Proceeds from Issuance of Private Placement |
|
|
64,000
|
|
|
|
|
|
|
|
| Payments of Stock Issuance Costs |
|
|
|
|
|
|
|
$ 5,500,000
|
|
|
| National Holdings Corporation [Member] | Mustang Bio, Inc [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Proceeds from Issuance of Private Placement |
|
|
$ 16,000
|
|
|
|
|
|
|
|
| Common Stock [Member] | Avenue Therapeutics, Inc. [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Shares Issued, Price Per Share |
|
|
|
|
|
$ 6.00
|
|
$ 6.00
|
|
|
| Stockholders' Equity, Reverse Stock Split |
|
|
|
|
|
|
|
3-For-1
|
|
|
| Research and Development Expense [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
$ 2,400,000
|
1,100,000
|
|
|
|
| General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
2,200,000
|
1,900,000
|
|
2,400,000
|
|
| General and Administrative Expense [Member] | Longterm Incentive Program [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation |
|
|
|
|
|
200,000
|
100,000
|
$ 300,000
|
100,000
|
|
| General and Administrative Expense [Member] | Helocyte Inc [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation |
|
|
|
|
|
8,000
|
25,000
|
$ 18,000
|
25,000
|
|
| Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition |
|
|
|
|
|
|
|
2 years 3 months 18 days
|
|
|
| Share-based Compensation |
|
|
|
|
|
64,000
|
100,000
|
$ 100,000
|
300,000
|
|
| Restricted Stock [Member] | Checkpoint Therapeutics, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation |
|
|
|
|
|
400,000
|
$ 400,000
|
1,000,000
|
700,000
|
|
| Restricted Stock [Member] | JMC [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation |
|
|
|
|
|
$ 4,000
|
|
$ 8,000
|
|
|
| Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition |
|
|
|
|
|
|
|
2 years 4 months 24 days
|
|
|
| Share-based Compensation |
|
|
|
|
|
|
|
$ 2,700,000
|
$ 6,400,000
|
|
| Employee Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Common Stock issued in connection with the first ESPP offering |
|
|
|
|
|
|
|
199,995
|
|
|
| Common Stock, Capital Shares Reserved for Future Issuance |
|
|
|
|
|
5
|
|
5
|
|
|
| Employee Stock Option [Member] | Journey Medical Corporation [Member] |
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate |
|
|
|
|
|
|
|
0.00%
|
|
|